The CHAMPION MG study was conducted to assess the effects of ravulizumab (Ultomiris) in patients with generalized myasthenia gravis (gMG).

The study researched whether ravulizumab improved symptoms, muscle strength and day-to-day life in patients with gMG, along with what side effects patients experienced.

The main study outcomes were changes from baseline in scores assessing ability to perform MG-related activities of daily living and muscle strength over 26 weeks of treatment with ravulizumab compared with placebo. At week 26, the improvements in both scores were significantly greater in the ravulizumab group than in the placebo group (see Fig. 1). The side effects of ravulizumab were generally mild and similar to placebo. They were also similar to those seen in studies of ravulizumab in other diseases.

Ravulizumab improved symptoms and muscle strength compared with placebo in patients with gMG who had acetylcholine receptor antibodies, and its side effects were mild in most patients.